Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Pamela A. Chatis is active.

Publication


Featured researches published by Pamela A. Chatis.


The New England Journal of Medicine | 1989

Acyclovir-Resistant Herpes Simplex Virus Infections in Patients with the Acquired Immunodeficiency Syndrome

Kim S. Erlich; John Mills; Pamela A. Chatis; Gregory J. Mertz; David F. Busch; Stephen E. Follansbee; Robert M. Grant; Clyde S. Crumpacker

RECURRENT herpes simplex virus (HSV) infections are frequent in patients with the acquired immunodeficiency syndrome (AIDS). Although they are usually self-limiting in the normal host, such infecti...


Antimicrobial Agents and Chemotherapy | 1992

Resistance of herpesviruses to antiviral drugs.

Pamela A. Chatis; Clyde S. Crumpacker

Images


Virology | 1991

Analysis of the thymidine kinase gene from clinically isolated acyclovir-resistant herpes simplex viruses

Pamela A. Chatis; Clyde S. Crumpacker

The isolation and description of acyclovir-resistant (ACVR) herpes simplex-2 viruses from patients with AIDS has recently been reported. These ACVR viruses were all markedly decreased in their thymidine kinase (TK) activity, and 6 of 10 of these TK viruses were able to establish latency. In addition, one of these isolates, ACVR-86012 was neuropathogenic in a murine encephalitis model. In this paper, the characteristics of these isolates with respect to TK polypeptide synthesis are examined. All but one isolate synthesized a detectable TK protein by immunoprecipitation, and 9/10 of the TK proteins had an altered electrophoretic mobility as compared to wild-type. The TK polypeptide from the neuropathogenic isolate ACVR-86012 was full-length and the gene was sequenced. An amino acid change from a glutamine to a proline at amino acid residue 105 was detected compared to the wild-type HSV-333 strain. These results indicate that an amino acid change in the NH2 portion of the TK protein is associated with a full-length peptide with decreased enzyme activity but the virus retains neuropathic virulence.


Virology | 1996

AZT-Related Mutation Lys70Arg in Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Confers Decrease in Susceptibility to ddATP inin VitroRT Inhibition Assay: Volume223,Number 2 (1996), pages 365–369

Prem L. Sharma; Pamela A. Chatis; Alex L. Dogon; Douglas L. Mayers; Francine E. McCutchan; Charlotte Page; Clyde S. Crumpacker

The genetic basis for didanosine (ddl) resistance in human immunodeficiency virus (HIV-1) has previously been shown to be commonly associated with a Leu to Val change at codon 74 in the HIV-1 RT gene. In this study sequential viral isolates were analyzed from five patients with prior zidovudine (AZT) use who received 6 to 16 months of ddl therapy. Following ddl therapy, viral isolates exhibited an increased AZT susceptibility and decreased ddl susceptibility. Sequence and nested PCR analysis of the HIV-1 RT gene revealed that two viral isolates contained the Leu to Val change at codon 74, and three other isolates with reduced susceptibility to ddl each contained changes at codons 65, 70, and 72. Site-directed mutagenesis was employed to insert specific mutations in RT gene of proviral clone pNL4-3. Analysis of virion-associated reverse transcriptase activity indicated that the Lys70Arg mutation resulted in an enzyme with 2- to 4-fold decreased susceptibility to ddATP. Statistical analysis of the inhibitory concentration for RT activity between pNL4-3 and mutant Lys70Arg viruses obtained in three independent RT inhibition assays was significant (P = 0.05) by student t test paired analysis. Drug susceptibility assays on the virus with Lys70Arg mutation showed a marginal decrease in susceptibility to ddl (1.5- to 2-fold) and about 4- to 6-fold decrease in susceptibility to AZT. Mutations Lys65Glu and Arg72Ser resulted in an impaired RT with greatly diminished functional RT activity. The AZT-associated Lys70Arg mutation results in an RT enzyme with decreased susceptibility to ddATP.


The New England Journal of Medicine | 1989

Successful Treatment with Foscarnet of an Acyclovir-Resistant Mucocutaneous Infection with Herpes Simplex Virus in a Patient with Acquired Immunodeficiency Syndrome

Pamela A. Chatis; C.H. Miller; L.E. Schrager; Clyde S. Crumpacker


Journal of Virology | 1991

In vitro suppression of normal human bone marrow progenitor cells by human immunodeficiency virus.

Howard N. Steinberg; Clyde S. Crumpacker; Pamela A. Chatis


Proceedings of the National Academy of Sciences of the United States of America | 1991

Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization.

Anthony J. Japour; Pamela A. Chatis; H A Eigenrauch; Clyde S. Crumpacker


Nucleic Acids Research | 2003

Directly labeled mRNA produces highly precise and unbiased differential gene expression data.

Vineet Gupta; Alex Cherkassky; Pamela A. Chatis; Richard Joseph; Andrew Johnson; Jeffrey Broadbent; Tom Erickson; James Joseph Dimeo


Virology | 1993

HIV Infection of the BS-1 Human Stroma Cell Line: Effect on Murine Hematopoiesis

Howard N. Steinberg; J. G. Anderson; Clyde S. Crumpacker; Pamela A. Chatis


Virology | 1993

Cytomegalovirus infection of the BS-1 human stroma cell line : effect on murine hemopoiesis

Howard N. Steinberg; J. G. Anderson; Bing Lim; Pamela A. Chatis

Collaboration


Dive into the Pamela A. Chatis's collaboration.

Top Co-Authors

Avatar

Clyde S. Crumpacker

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Francine E. McCutchan

Henry M. Jackson Foundation for the Advancement of Military Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge